Results for Cell Specification

Dr. Gadue studies cell fate decisions, focusing on endoderm and mesoderm specification using human embryonic stem (ES) cells and induced pluripotent stem (iPS).

Dr. Marks investigates the molecular mechanisms underlying the formation of cell type-specific lysosome-related organelles; the assembly, delivery and function of their contents; and how these processes are impacted by genetic diseases.

Dr. Weber is developing approaches to enhance CAR-T cell therapies for pediatric cancer by reprogramming T cells with improved durability and exhaustion resistance. His work will uncover molecular mechanisms that promote CAR-T cell exhaustion and identify new targets for therapeutic intervention.

Dr. Roizen's research program aims to understand non-calciometabolic effects of vitamin D and to use this understanding to design new therapeutic approaches to common diseases such as sarcopenia and obesity.

Dr. Kadauke is the associate director of the Cell and Gene Therapy Laboratory at CHOP and the medical director of the Cell and Gene Therapy Informatics team. His research focuses on developing novel ways to manufacture cell therapies with the goal of accelerating and broadening patient access to these life-saving therapies.

Dr. Ma focuses on immune engineering. He leverages genetic, chemistry, and engineering tools to dissect immune cell-cell and cell-tissue crosstalk and harness these crosstalk mechanisms to develop biomaterials, protein, and cell-based precision immunotherapies for cancer and autoimmune diseases.

Dr. Lefebvre investigates the genetic mechanisms that generate the diversity of cell types composing the body. Her emphasis is on deciphering how proteins called SOX transcription factors specify stem cells and highly specialized cells in the skeleton, how changes in these factors cause skeletal diseases, and how these factors also control other processes, including brain development and intellectual disability diseases.

Dr. Samelson-Jones is a pediatric hematologist dedicated to improving the lives of children with bleeding and clotting disorders. His research focuses on gene therapy for hemophilia, the biochemical basis of coagulation, and the immune responses to hemophilia therapies.

Dr. Tan uses experimental and computational approaches to study normal development and cancer. His laboratory is using the integrative approach to dissect the gene regulatory networks controlling embryonic hematopoiesis, T cell differentiation, and oncogenesis. He is also developing computational algorithms for constructing models of transcriptional regulatory and signaling networks by integrating multi-dimensional genomic, epigenomic, and transcriptomic datasets.

Dr. Olson aims to improve diagnostics and treatment of bone marrow failure (BMF) syndromes, and to improve clinical hematopoietic stem cell transplantation (HSCT) outcomes. He conducts clinical trials of HSCT for non-malignant hematologic diseases. His laboratory explores both basic and translational research focused on genomics of BMF and the impact of BMF on hematopoietic niche function during HSCT.